• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Operating Officer Gault Cheryl was granted 13,987 shares, increasing direct ownership by 9% to 171,928 units (SEC Form 4)

    3/5/25 5:00:09 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Gault Cheryl

    (Last) (First) (Middle)
    RAPPORT THERAPEUTICS, INC.
    1325 BOYLSTON STREET, SUITE 401

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Rapport Therapeutics, Inc. [ RAPP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Operating Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/03/2025 A 13,987(1) A $0 171,928 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in two equal annual installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.
    /s/ Troy Ignelzi, Attorney-in-Fact 03/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RAPP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAPP

    DatePrice TargetRatingAnalyst
    4/8/2025Mkt Outperform
    Citizens JMP
    7/2/2024Buy
    TD Cowen
    7/2/2024$35.00Buy
    Jefferies
    7/2/2024$35.00Buy
    Stifel
    More analyst ratings

    $RAPP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Bredt David sold $81,262 worth of shares (8,500 units at $9.56), decreasing direct ownership by 2% to 452,142 units (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      5/19/25 4:30:28 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Bredt David sold $81,310 worth of shares (8,500 units at $9.57), decreasing direct ownership by 2% to 460,642 units (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      4/16/25 5:00:04 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Sevigny Jeffrey

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      4/3/25 5:00:07 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Rapport Therapeutics

      Citizens JMP initiated coverage of Rapport Therapeutics with a rating of Mkt Outperform

      4/8/25 9:31:03 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Rapport Therapeutics

      TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy

      7/2/24 8:03:15 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Rapport Therapeutics with a new price target

      Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00

      7/2/24 7:51:37 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Rapport Therapeutics Inc.

      SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/14/24 5:13:31 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rapport Therapeutics Inc.

      SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/14/24 3:11:15 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rapport Therapeutics Inc.

      SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/13/24 12:26:41 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Leadership Updates

    Live Leadership Updates

    See more
    • Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

      3/11/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

      BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

      3/3/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

      Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is

      11/7/24 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

      BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport's executive team on the Company's strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event's agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone's Comprehensive Epileps

      6/2/25 2:45:00 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

      BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) - fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time. Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL) - fireside chat on Monday, June 9, 2025, at 10:00 a.m. Eastern Time. Interested parties may access the live and archived webc

      5/27/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics to Host 2025 Investor and Analyst Day

      BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced it will host its inaugural Investor and Analyst Day on Monday, June 2, 2025, in New York City. The event will also be webcast live. Rapport senior management will review the company's clinical programs, with a focus on the RAP-219 Phase 2a trial in refractory focal epilepsy. The event will also feature a fireside chat with Dr. Jacqueline A. French—a globally recognized leader in epilepsy research, profes

      5/21/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Ignelzi Troy A. bought $100,988 worth of shares (10,000 units at $10.10) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      3/13/25 5:13:57 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Young Wendy B. bought $61,250 worth of shares (6,000 units at $10.21) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      3/13/25 5:00:03 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Healy James bought $1,079,575 worth of shares (44,032 units at $24.52) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      7/3/24 8:04:04 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    SEC Filings

    See more
    • Rapport Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

      6/2/25 4:07:20 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rapport Therapeutics Inc.

      10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)

      5/8/25 7:30:23 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

      5/8/25 7:15:09 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care